TrippBio is founded on the research of Ralph Tripp, Ph.D. the Georgia Research Alliance chair and Professor at the University of Georgia.
Dr. Moti N. Ramgopal of Midway Immunology and Research Center launched the investigator-initiated study to assess the efficacy of TD213 in treating patients with confirmed mild - moderate COVD-19 infections.
Ramgopal announced the final patient was enrolled in this proof of concept study and all participants are progressing through the protocol designated testing and follow-up visits. Recognized as one of the leading infectious disease doctors in the United States, Dr. Ramgopal's research center is committed to all the health needs of the patient.
TrippBio is a SpinUp Campus company. SpinUp Campus focuses on connecting university scientists with public investors to transform groundbreaking research into viable businesses that can change the world.
TrippBio said it needs the support of the worldwide community to continue into the next phase of testing and will use the capital from ongoing equity crowdfunding to extend clinical trials needed to seek global regulatory approval and commercialization of TD213.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial